You can seek FDA approval to launch a generic drug before the expiration of ALOXI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ALOXI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ALOXI:-

You can seek FDA approval to launch a generic drug before the expiration of ATRIPLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ATRIPLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ATRIPLA:-

You can seek FDA approval to launch a generic drug before the expiration of AVANDAMET's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AVANDAMET's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AVANDAMET:-

You can seek FDA approval to launch a generic drug before the expiration of AVANDARYL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AVANDARYL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AVANDARYL:-

You can seek FDA approval to launch a generic drug before the expiration of AVANDIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AVANDIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AVANDIA:-

You can seek FDA approval to launch a generic drug before the expiration of AVODART's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AVODART's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AVODART:-

You can seek FDA approval to launch a generic drug before the expiration of AXERT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AXERT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AXERT:-

You can seek FDA approval to launch a generic drug before the expiration of BARACLUDE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BARACLUDE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BARACLUDE:-

You can seek FDA approval to launch a generic drug before the expiration of COMPLERA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMPLERA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMPLERA:-

You can seek FDA approval to launch a generic drug before the expiration of DESCOVY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DESCOVY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DESCOVY:-

You can seek FDA approval to launch a generic drug before the expiration of DORIBAX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DORIBAX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DORIBAX:-

You can seek FDA approval to launch a generic drug before the expiration of DOVONEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DOVONEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DOVONEX:-

You can seek FDA approval to launch a generic drug before the expiration of DOVONEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DOVONEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DOVONEX:-

You can seek FDA approval to launch a generic drug before the expiration of EMEND's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EMEND's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EMEND:-

You can seek FDA approval to launch a generic drug before the expiration of EMTRIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EMTRIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EMTRIVA:-

You can seek FDA approval to launch a generic drug before the expiration of ENABLEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ENABLEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ENABLEX:-

You can seek FDA approval to launch a generic drug before the expiration of FOCALIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FOCALIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FOCALIN:-

You can seek FDA approval to launch a generic drug before the expiration of GENVOYA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GENVOYA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GENVOYA:-

You can seek FDA approval to launch a generic drug before the expiration of GLEEVEC's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GLEEVEC's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GLEEVEC:-

You can seek FDA approval to launch a generic drug before the expiration of INVANZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the INVANZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on INVANZ:-

You can seek FDA approval to launch a generic drug before the expiration of JALYN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JALYN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JALYN:-

You can seek FDA approval to launch a generic drug before the expiration of KALETRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KALETRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KALETRA:-

You can seek FDA approval to launch a generic drug before the expiration of LETAIRIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LETAIRIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LETAIRIS:-

You can seek FDA approval to launch a generic drug before the expiration of LIVALO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LIVALO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LIVALO:-

You can seek FDA approval to launch a generic drug before the expiration of MYCAMINE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MYCAMINE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MYCAMINE:-

You can seek FDA approval to launch a generic drug before the expiration of ODEFSEY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ODEFSEY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ODEFSEY:-

You can seek FDA approval to launch a generic drug before the expiration of SENSIPAR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SENSIPAR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SENSIPAR:-

You can seek FDA approval to launch a generic drug before the expiration of STRIBILD's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STRIBILD's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STRIBILD:-

You can seek FDA approval to launch a generic drug before the expiration of TACLONEX's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TACLONEX's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TACLONEX:-

You can seek FDA approval to launch a generic drug before the expiration of TAMIFLU's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TAMIFLU's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TAMIFLU:-

You can seek FDA approval to launch a generic drug before the expiration of TRUVADA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRUVADA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRUVADA:-

You can seek FDA approval to launch a generic drug before the expiration of VALCYTE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VALCYTE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VALCYTE:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of ZYMAXID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZYMAXID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZYMAXID:-